Literature DB >> 30945700

Upregulation of miR150-5p in generalized myasthenia gravis patients is associated with decreased serum levels of IL-17 and increased serum levels of IL-10.

Wenling Ao1, Canhui Tian1, Xiongjun He1, Yeli Hu1, Weidong Wang1, Yajie Liu1.   

Abstract

BACKGROUND: MiR150-5p has been reported to be involved in generalized myasthenia gravis, in which different cytokines play critical roles. The regulatory network of cytokines in generalized myasthenia gravis has not been fully elucidated. Our study aimed to investigate the interactions between miR150-5p and different cytokines in generalized myasthenia gravis. MATERIALS AND
METHOD: Serum levels of miR150-5p and different cytokines including IL-2, IL-17, IL-10, IL-19, IL-20 and IL-35 were detected by qRT-PCR and ELISA, respectively. ROC curve analysis was performed to evaluate the diagnostic value of miR150-5p for generalized myasthenia gravis. Correlation between serum levels of miR150-5p and different cytokines were analyzed by Pearson correlation coefficient.
RESULTS: Compared with healthy controls, decreased serum levels of IL-2 and IL-17 and increased serum levels of miR150-5p, IL-10, IL-19, IL-20 and IL-35 were observed in patients with generalized myasthenia gravis. Serum levels of miR150-5p were positively correlated with IL-10 and negatively correlated with IL-17. After treatments, serum levels of miR150-5p and IL-10 decreased, while serum levels of IL-2 and IL-17 increased.
CONCLUSION: Upregulation of miR150-5p is involved in generalized myasthenia gravis patients and is associated with decreased serum levels of IL-17 as well as increased serum levels of IL-10.

Entities:  

Keywords:  MiR150-5p; cytokines; generalized myasthenia gravis

Mesh:

Substances:

Year:  2019        PMID: 30945700     DOI: 10.5507/bp.2019.009

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  5 in total

1.  Long non-coding RNA growth arrest specific 5 regulates the T helper 17/regulatory T balance by targeting miR-23a in myasthenia gravis.

Authors:  Yingying Xu; Yiqun Ouyang
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573

2.  Effects of Plasma Exchange Combined with Immunoglobulin Therapy on Consciousness, Immune Function, and Prognosis in Patients with Myasthenia Gravis Crisis: A Prospective Randomized Test.

Authors:  Xu Peng; Xiao-Bi Xie; Hong Tan; Dan Zhang; Bo-Tao Jiang; Jie Liu; Shuang Li; Ya-Rui Chen; Tao-Yang Xie
Journal:  Comput Math Methods Med       Date:  2022-06-30       Impact factor: 2.809

Review 3.  A Review on the Role of Non-Coding RNAs in the Pathogenesis of Myasthenia Gravis.

Authors:  Soudeh Ghafouri-Fard; Tahereh Azimi; Bashdar Mahmud Hussen; Mohammad Taheri; Reza Jalili Khoshnoud
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

4.  MiR-522-3p inhibits proliferation and activation by regulating the expression of SLC31A1 in T cells.

Authors:  Hengxiao Lu; Hao Wang; Peidao Sun; Jiang Wang; Shuhai Li; Tongzhen Xu
Journal:  Cytotechnology       Date:  2021-05-07       Impact factor: 2.040

5.  Upregulation of circ-FBL promotes myogenic proliferation in myasthenia gravis by regulation of miR-133/PAX7.

Authors:  Xiaoyin Lai; Zhuajin Bi; Xuelian Yang; Rongguo Hu; Lu Wang; Mingming Jin; Longxuan Li; Bitao Bu
Journal:  Cell Biol Int       Date:  2021-08-07       Impact factor: 4.473

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.